ARTICLE - Iron Metabolism & its Disorders

Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions

Natarajaswamy Kalleda, Anna Flace, Patrick Altermatt, Giada Ingoglia,° Cédric Doucerain,° Naja Nyffenegger, Franz Dürrenberger and Vania Manolova

Research and Non-clinical Development, CSL Vifor, St. Gallen, Switzerland

°GI current address: Avelo AG, Schlieren, Switzerland.
°CD current address: Anjarium Biosciences, Zurich, Switzerland.

Correspondence: N. Kalleda
natarajaswamy.kalleda@viforpharma.com

Received: October 28, 2022.
Accepted: May 4, 2023.
Early view: May 11, 2023.

https://doi.org/10.3324/haematol.2022.282328

SUPPLEMENTAL MATERIAL

Figure S1. NTBI levels in Hbb$^{th3/+}$ mice after vamifeport treatment alone or in combination with repeated blood transfusions. Representative scatter plot of individual values (with mean and standard deviation) showing the effects of transfusion, vehicle, and vamifeport treatment at the end of the study. NTBI, non-transferrin-bound iron; WT, wild-type. There were no significant differences for statistical comparisons between any treatment group and the Hbb$^{th3/+}$ vehicle non-transfused group or the vehicle transfused group.



Figure S2. Spleen weight, spleen iron and *Erfe expression* in Hbb$^{th3/+}$ mice after vamifeport treatment alone or in combination with repeated blood transfusions. Representative scatter plots of individual values (with mean and standard deviation) showing the effects of transfusion, vehicle, and vamifeport treatment at the end of the study on **A**. Relative spleen weight, **B**. Spleen iron content, **C**. Spleen iron concentration, **D**. *Erfe* expression. *Erfe*, erythroferrone; WT, wild-type. Significant differences compared with the Hbb$^{th3/+}$ vehicle non-transfused group (black) and vehicle transfused group (purple) are indicated as: *p<0.05, **p<0.01, and ***p<0.001.



Figure S3. Liver, heart, and kidney iron concentration in Hbb$^{th3/+}$ mice after vamifeport treatment alone or in combination with repeated blood transfusions. Representative scatter plots of individual values (with mean and standard deviation) showing the effects of transfusion, vehicle, and vamifeport treatment at the end of the study on total **A.** Liver iron, **B.** Heart iron, **C.** Kidney iron. WT, wild-type. Significant differences compared with the Hbb$^{th3/+}$ vehicle non-transfused group (black) and vehicle transfused group (purple) are indicated as: *p<0.05, **p<0.01, and ***p<0.001.